Cargando…

Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging

Fibroblast activation protein (FAP) is regarded as a promising target for the diagnosis and treatment of tumors as it was overexpressed in cancer-associated fibroblasts. FAP inhibitors bearing a quinoline scaffold have been proven to show high affinity against FAP in vitro and in vivo, and the scaff...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ni, Pan, Fei, Pan, Lili, Diao, Wei, Su, Feijing, Huang, Rui, Yang, Bo, Li, Yunchun, Qi, Zhongzhi, Zhang, Wenjie, Wu, Xiaoai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086185/
https://www.ncbi.nlm.nih.gov/pubmed/37057133
http://dx.doi.org/10.3389/fbioe.2023.1167329
_version_ 1785022093620936704
author Zhang, Ni
Pan, Fei
Pan, Lili
Diao, Wei
Su, Feijing
Huang, Rui
Yang, Bo
Li, Yunchun
Qi, Zhongzhi
Zhang, Wenjie
Wu, Xiaoai
author_facet Zhang, Ni
Pan, Fei
Pan, Lili
Diao, Wei
Su, Feijing
Huang, Rui
Yang, Bo
Li, Yunchun
Qi, Zhongzhi
Zhang, Wenjie
Wu, Xiaoai
author_sort Zhang, Ni
collection PubMed
description Fibroblast activation protein (FAP) is regarded as a promising target for the diagnosis and treatment of tumors as it was overexpressed in cancer-associated fibroblasts. FAP inhibitors bearing a quinoline scaffold have been proven to show high affinity against FAP in vitro and in vivo, and the scaffold has been radio-labeled for the imaging and treatment of FAP-positive tumors. However, currently available FAP imaging agents both contain chelator groups to enable radio-metal labeling, making those tracers more hydrophilic and not suitable for the imaging of lesions in the brain. Herein, we report the synthesis, radio-labeling, and evaluation of a (18)F-labeled quinoline analogue ([(18)F]3) as a potential FAP-targeted PET tracer, which holds the potential to be blood–brain barrier-permeable. [(18)F]3 was obtained by one-step radio-synthesis via a copper-mediated S(N)A(R) reaction from a corresponding boronic ester precursor. [(18)F]3 showed moderate lipophilicity with a log D ( 7.4 ) value of 1.11. In cell experiments, [(18)F]3 showed selective accumulation in A549-FAP and U87 cell lines and can be effectively blocked by the pre-treatment of a cold reference standard. Biodistribution studies indicated that [(18)F]3 was mainly excreted by hepatic clearance and urinary excretion, and it may be due to its moderate lipophilicity. In vivo PET imaging studies indicated [(18)F]3 showed selective accumulation in FAP-positive tumors, and specific binding was confirmed by blocking studies. However, low brain uptake was observed in biodistribution and PET imaging studies. Although our preliminary data indicated that [(18)F]3 holds the potential to be developed as a blood–brain barrier penetrable FAP-targeted PET tracer, its low brain uptake limits its application in the detection of brain lesions. Herein, we report the synthesis and evaluation of [(18)F]3 as a novel small-molecule FAPI-targeted PET tracer, and our results suggest further structural optimizations would be needed to develop a BBB-permeable PET tracer with this scaffold.
format Online
Article
Text
id pubmed-10086185
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100861852023-04-12 Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging Zhang, Ni Pan, Fei Pan, Lili Diao, Wei Su, Feijing Huang, Rui Yang, Bo Li, Yunchun Qi, Zhongzhi Zhang, Wenjie Wu, Xiaoai Front Bioeng Biotechnol Bioengineering and Biotechnology Fibroblast activation protein (FAP) is regarded as a promising target for the diagnosis and treatment of tumors as it was overexpressed in cancer-associated fibroblasts. FAP inhibitors bearing a quinoline scaffold have been proven to show high affinity against FAP in vitro and in vivo, and the scaffold has been radio-labeled for the imaging and treatment of FAP-positive tumors. However, currently available FAP imaging agents both contain chelator groups to enable radio-metal labeling, making those tracers more hydrophilic and not suitable for the imaging of lesions in the brain. Herein, we report the synthesis, radio-labeling, and evaluation of a (18)F-labeled quinoline analogue ([(18)F]3) as a potential FAP-targeted PET tracer, which holds the potential to be blood–brain barrier-permeable. [(18)F]3 was obtained by one-step radio-synthesis via a copper-mediated S(N)A(R) reaction from a corresponding boronic ester precursor. [(18)F]3 showed moderate lipophilicity with a log D ( 7.4 ) value of 1.11. In cell experiments, [(18)F]3 showed selective accumulation in A549-FAP and U87 cell lines and can be effectively blocked by the pre-treatment of a cold reference standard. Biodistribution studies indicated that [(18)F]3 was mainly excreted by hepatic clearance and urinary excretion, and it may be due to its moderate lipophilicity. In vivo PET imaging studies indicated [(18)F]3 showed selective accumulation in FAP-positive tumors, and specific binding was confirmed by blocking studies. However, low brain uptake was observed in biodistribution and PET imaging studies. Although our preliminary data indicated that [(18)F]3 holds the potential to be developed as a blood–brain barrier penetrable FAP-targeted PET tracer, its low brain uptake limits its application in the detection of brain lesions. Herein, we report the synthesis and evaluation of [(18)F]3 as a novel small-molecule FAPI-targeted PET tracer, and our results suggest further structural optimizations would be needed to develop a BBB-permeable PET tracer with this scaffold. Frontiers Media S.A. 2023-03-28 /pmc/articles/PMC10086185/ /pubmed/37057133 http://dx.doi.org/10.3389/fbioe.2023.1167329 Text en Copyright © 2023 Zhang, Pan, Pan, Diao, Su, Huang, Yang, Li, Qi, Zhang and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Zhang, Ni
Pan, Fei
Pan, Lili
Diao, Wei
Su, Feijing
Huang, Rui
Yang, Bo
Li, Yunchun
Qi, Zhongzhi
Zhang, Wenjie
Wu, Xiaoai
Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging
title Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging
title_full Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging
title_fullStr Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging
title_full_unstemmed Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging
title_short Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging
title_sort synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (fap) pet imaging
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086185/
https://www.ncbi.nlm.nih.gov/pubmed/37057133
http://dx.doi.org/10.3389/fbioe.2023.1167329
work_keys_str_mv AT zhangni synthesisradiolabelingandevaluationofa4quinolinoylglycyl2cyanopyrrolidineanalogueforfibroblastactivationproteinfappetimaging
AT panfei synthesisradiolabelingandevaluationofa4quinolinoylglycyl2cyanopyrrolidineanalogueforfibroblastactivationproteinfappetimaging
AT panlili synthesisradiolabelingandevaluationofa4quinolinoylglycyl2cyanopyrrolidineanalogueforfibroblastactivationproteinfappetimaging
AT diaowei synthesisradiolabelingandevaluationofa4quinolinoylglycyl2cyanopyrrolidineanalogueforfibroblastactivationproteinfappetimaging
AT sufeijing synthesisradiolabelingandevaluationofa4quinolinoylglycyl2cyanopyrrolidineanalogueforfibroblastactivationproteinfappetimaging
AT huangrui synthesisradiolabelingandevaluationofa4quinolinoylglycyl2cyanopyrrolidineanalogueforfibroblastactivationproteinfappetimaging
AT yangbo synthesisradiolabelingandevaluationofa4quinolinoylglycyl2cyanopyrrolidineanalogueforfibroblastactivationproteinfappetimaging
AT liyunchun synthesisradiolabelingandevaluationofa4quinolinoylglycyl2cyanopyrrolidineanalogueforfibroblastactivationproteinfappetimaging
AT qizhongzhi synthesisradiolabelingandevaluationofa4quinolinoylglycyl2cyanopyrrolidineanalogueforfibroblastactivationproteinfappetimaging
AT zhangwenjie synthesisradiolabelingandevaluationofa4quinolinoylglycyl2cyanopyrrolidineanalogueforfibroblastactivationproteinfappetimaging
AT wuxiaoai synthesisradiolabelingandevaluationofa4quinolinoylglycyl2cyanopyrrolidineanalogueforfibroblastactivationproteinfappetimaging